Moksha8 Pharmaceuticals has expanded its partnership with Roche to commercialise an additional portfolio of products in Mexico and Brazil.
The company will commercialise products in three therapeutic areas – CNS disease, anti-infectives and inflammation. The product portfolio covers brands like Rivotril, Rocephin and Bactrim.
Roche Latin America President Ernest Egli said that Moksha8 had produced strong results for Roche in Brazil and was delighted to expand the relationship to include Mexico as a key country.
Moksha8 is positioned as the partner of choice for pharmaceutical and biotechnology companies seeking to capture value from their products in high-growth emerging markets.
The company has a strong presence in the CNS, anti-infectives and inflammation markets in Latin America.